Table 3 Market shares of conventional recombinant products for paediatric and adult patients
| Â | Paediatrics | Adults |
|---|---|---|
Advate® | 30% | 24% |
Kogenate® | 29% | 23% |
Refacto® | 23% | 18% |
Helixate® | 17% | 13% |
Recombinate® | 1% | 1% |
Plasma-derived products | – | 21% |
| Â | Paediatrics | Adults |
|---|---|---|
Advate® | 30% | 24% |
Kogenate® | 29% | 23% |
Refacto® | 23% | 18% |
Helixate® | 17% | 13% |
Recombinate® | 1% | 1% |
Plasma-derived products | – | 21% |